Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With.

Slides:

Advertisements

Similar presentations

C-Met Inhibitor MK-8003 Radiosensitizes c-Met–Expressing Non–Small-Cell Lung Cancer Cells With Radiation-Induced c-Met–Expression Vikas Bhardwaj, PhD,

Advertisements

Preoperative Evaluations: The Very Last Chance To Identify a Problem With a Pacemaker or Implanted Cardioverter-Defibrillator Marc A. Rozner, PhD, MD Journal.

A Quantitative Analysis of the Relationship Between Radiation Therapy Use and Travel Time Emma Liu, MM, Pablo Santibáñez, MM, Martin L. Puterman, PhD,

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate.

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Chris H. J. Terhaard, M. D. , Ph. D. , Herman Lubsen, M. D. , Ph. D

COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results.

Non-randomized comparison between definitive concurrent chemoradiotherapy and preoperative radiotherapy followed by surgery in patients with hypopharyngeal.

Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer Nadya Shusharina, PhD,

The Case for Prostate Brachytherapy in the Affordable Care Act Era

Benjamin D. Rosenbluth, M. D. , Victoria Serrano, B. S

The Role of Diffusion-Weighted Magnetic Resonance Imaging in the Treatment Response Evaluation of Hepatocellular Carcinoma Patients Treated With Radiation.

The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study Alan M. Nichol,

Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer

A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer Ludmila Katherine Martin, MD,

18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy

Dose-Volume Histogram Predictors of Chronic Gastrointestinal Complications After Radical Hysterectomy and Postoperative Concurrent Nedaplatin-Based Chemoradiation.

T. Liu, J. Zhou, S. A. Woodhouse, P. B. Schiff, P. Zhang, K. S

Lactate-Base 1H Magnetic Spectroscopy Does Not Predict Response and Outcomes in Patients With Stage IV Head and Neck Squamous Cell Carcinoma Q. Le, A.

Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy:

Close or Positive Margins After Mastectomy for DCIS: Pattern of Relapse and Potential Indications for Radiotherapy Afshin Rashtian, M.D., Shawn Iganej,

Ductal Carcinoma In Situ With Microinvasion: Prognostic Implications, Long-Term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, M.D., Bruce.

The impact of ipsilateral breast tumor recurrence on cause specific survival in DCIS patients treated with breast conserving therapy or mastectomy C.

Morten Hoyer, Ph. D. , Henrik Roed, D. M. Sc

Jerry D Slater, M. D. , Carl J Rossi, M. D. , Les T Yonemoto, M. D

Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate.

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

Obituary and Tribute to John “Jack” Francis Fowler, PhD, DSc ( )

Continuing Risk of Ipsilateral Breast Relapse After Breast-Conserving Therapy at Long- Term Follow-up Bas Kreike, M.D., Augustinus A.M. Hart, M.Sc., Tony.

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.

Lifetime Increased Cancer Risk in Mice Following Exposure to Clinical Proton Beam– Generated Neutrons Leo E. Gerweck, PhD, Peigen Huang, MD, Hsiao-Ming.

Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials Gustavo Arruda Viani,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases Isabelle Thibault, MD, Mikki Campbell,

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

International Journal of Radiation Oncology • Biology • Physics

Radiation Therapy and Hearing Loss

High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian, M.D., Vivian Weinberg, Ph.D.,

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Prospective Study of Patient-Reported Symptom Burden in Patients With Non–Small- Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy Xin.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Esophageal Cancer Located at the Neck and Upper Thorax Treated with Concurrent Chemoradiation: A Single-Institution Experience Shulian Wang, MD, Zhongxing.

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent.

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Liru He, MD, Pamela K. Allen, PhD, Adam.

PD5-2-5: Local therapy of primary diseae improves survival in non-small cell lung cancer metastatic to a single organ - a lesson from brain metastases

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma Mitchell Machtay, MD, Rebecca Paulus, BS, Jennifer.

Treatment of Colorectal Cancer

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Association between Systemic Chemotherapy before Chemoradiation and Increased Risk of Treatment-Related Pneumonitis in Esophageal Cancer Patients Treated.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

RTOG 0017: A Phase I Trial of Concurrent Gemcitabine/Carboplatin or Gemcitabine/Paclitaxel and Radiation Therapy (“Ping-Pong Trial”) Followed By Adjuvant.

Superior sulcus lung tumors: Impact of local control on survival

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

PD6-1-6: Mid-course resimulation for small cell lung cancer patients receiving definitive chemoradiation: sparing of normal lung and esophagus without.

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Presentation transcript:

Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group Mitchell Machtay, M.D., Kyounghwa Bae, Ph.D., Benjamin Movsas, M.D., Rebecca Paulus, B.S., Elizabeth M. Gore, M.D., Ritsuko Komaki, M.D., Kathy Albain, M.D., William T. Sause, M.D., Walter J. Curran, M.D. International Journal of Radiation Oncology • Biology • Physics Volume 82, Issue 1, Pages 425-434 (January 2012) DOI: 10.1016/j.ijrobp.2010.09.004 Copyright © 2012 Elsevier Inc. Terms and Conditions

Fig. 1 Biologically effective dose (BED) and time-adjusted BED (tBED) formulae. International Journal of Radiation Oncology • Biology • Physics 2012 82, 425-434DOI: (10.1016/j.ijrobp.2010.09.004) Copyright © 2012 Elsevier Inc. Terms and Conditions

Fig. 2 Actuarial Local failure. BED = biologically effective dose; tBED = time-adjusted BED. International Journal of Radiation Oncology • Biology • Physics 2012 82, 425-434DOI: (10.1016/j.ijrobp.2010.09.004) Copyright © 2012 Elsevier Inc. Terms and Conditions

Fig. 3 Actuarial Survival. BED = biologically effective dose; tBED = time-adjusted BED. International Journal of Radiation Oncology • Biology • Physics 2012 82, 425-434DOI: (10.1016/j.ijrobp.2010.09.004) Copyright © 2012 Elsevier Inc. Terms and Conditions